295 related articles for article (PubMed ID: 29208258)
1. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
2. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
[TBL] [Abstract][Full Text] [Related]
5. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
[TBL] [Abstract][Full Text] [Related]
7. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
[TBL] [Abstract][Full Text] [Related]
8. Lymphangioleiomyomatosis (LAM) presenting as recurrent pneumothorax in an infant with tuberous sclerosis: treated successfully with sirolimus.
Takia L; Jat KR; Mandal A; Kabra SK
BMJ Case Rep; 2018 Nov; 2018():. PubMed ID: 30413450
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis.
Johnson SR; Taveira-DaSilva AM; Moss J
Clin Chest Med; 2016 Sep; 37(3):389-403. PubMed ID: 27514586
[TBL] [Abstract][Full Text] [Related]
10. Summaries for patients. Sirolimus therapy in patients with lymphangioleiomyomatosis.
Ann Intern Med; 2011 Jun; 154(12):I44. PubMed ID: 21690578
[No Abstract] [Full Text] [Related]
11. [Pulmonary lymphangioleiomyomatosis: presentation and results of treatment].
Korzeniewska-Koseła M; Maziarka D; Wesołowski S; Langfort R; Słodkowska J; Bestry I; Kowalski J; Kuś J
Pneumonol Alergol Pol; 2001; 69(11-12):626-34. PubMed ID: 12134438
[TBL] [Abstract][Full Text] [Related]
12. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
[TBL] [Abstract][Full Text] [Related]
13. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
[TBL] [Abstract][Full Text] [Related]
14. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis.
Namba M; Masuda T; Nakamura T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Intern Med; 2017 Dec; 56(24):3327-3331. PubMed ID: 29021448
[TBL] [Abstract][Full Text] [Related]
15. Lymphangioleiomyomatosis treatment with sirolimus.
Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
[TBL] [Abstract][Full Text] [Related]
16. [A rare cause of edema: sporadic lymphangioleiomyomatosis].
Frank H; Weiss W
Dtsch Med Wochenschr; 2013 Sep; 138(38):1892-5. PubMed ID: 24022453
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
Ando K; Kurihara M; Kataoka H; Ueyama M; Togo S; Sato T; Doi T; Iwakami S; Takahashi K; Seyama K; Mikami M
Respir Investig; 2013 Sep; 51(3):175-83. PubMed ID: 23978644
[TBL] [Abstract][Full Text] [Related]
18. Lymphangioleiomyomatosis.
Sclafani A; VanderLaan P
N Engl J Med; 2018 Jun; 378(23):2224. PubMed ID: 29874537
[No Abstract] [Full Text] [Related]
19. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.
Sugimoto R; Nakao A; Yamane M; Toyooka S; Okazaki M; Aoe M; Seyama K; Date H; Oto T; Sano Y
J Heart Lung Transplant; 2008 Aug; 27(8):921-4. PubMed ID: 18656809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]